| Literature DB >> 28294549 |
Zenghui Cheng1,2, Fei Shan1, Jinxin Liu3, Yuxin Shi1, Zhiyong Zhang1,4,5, Guowei Wu6.
Abstract
BACKGROUND: The study was conducted to investigate clinical and computed tomography (CT) features in Chinese lung cancer patients with human immunodeficiency virus (HIV).Entities:
Keywords: Acquired immunodeficiency syndrome, computed tomography, human immunodeficiency virus, lung cancer
Mesh:
Year: 2017 PMID: 28294549 PMCID: PMC5415480 DOI: 10.1111/1759-7714.12429
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Clinical data of 40 patients with lung cancer and HIV infection
| Case No./Gender/Age | CC | Smoking (pack‐years) | OPI | HIV‐RNA (copies/mL) | CD4 (cells/μL) | HAART (months) | Histology | TNM/stage |
|---|---|---|---|---|---|---|---|---|
| 1/M/40 | Bloody phlegm | 0 | No | NA | 522 | 3 | ADC | pT2bN0M0/IIa |
| 2/M/52 | Cough, chest pain | 60 | No | 83 500 | 223 | 0 | SCLC | ED |
| 3/M/50 | Cough, expectoration | 15 | TB | <40 | 464 | 24 | ADC | cT3N2M1a/IV |
| 4/F/51 | Fatigue | 0 | No | 142 | 319 | NA | ADC | pT2aN0M0/Ib |
| 5/M/62 | Cough, expectoration | 30 | TB | 50.4 | 38 | 9 | ADC | cTxN3M1b/IV |
| 6/M/57 | Cough, polypnea | 0 | TB, NTM | 183 | 127 | 0 | SCLC | LD |
| 7/M/55 | Cough | 0 | No | <40 | 594 | 96 | LCNEC | pT1bN0M0/Ia |
| 8/M/44 | Cough | 60 | TB, F | NA | 98 | 36 | SCC | cT2aN3M0/IIIb |
| 9/M/51 | Chest pain | 60 | TB | NA | 213 | 0 | SCC | cT3N3M1a/IV |
| 10/M/50 | None | 20 | No | NA | 266 | 24 | ADC | pT2aN0M0/Ib |
| 11/M/44 | Bloody phlegm | 0 | NTM, F | <40 | 111 | 36 | ADC | pT2bN2M0/IIIa |
| 12/M/59 | Cough, bloody phlegm | 30 | TB | NA | 263 | 0 | LCC | pT3N0M0/IIb |
| 13/M/77 | Cough, expectoration | 0 | No | 40 | 274 | 0 | SCC | pT1bN0M0/Ia |
| 14/F/59 | Bloody phlegm | 0 | TB | <40 | 373 | 24 | AC | pT3N0M0/IIb |
| 15/M/53 | Chest tightness, polypnea | 0 | No | NA | 281 | 24 | ADC | cT4N2M1a/IV |
| 16/M/67 | Cough | 48 | No | NA | 341 | 0 | SCLC | ED |
| 17/F/62 | Cough | 0 | No | NA | 204 | 0 | ADC | pT1aN0M0/Ia |
| 18/M/60 | Cough, bloody phlegm, chest pain | 60 | No | <40 | 235 | 72 | SCC | cT4N1M0/IIIa |
| 19/M/65 | Cough | 0 | F | NA | 145 | 0 | ADC | cT1bN0M0/Ia |
| 20/M/59 | None | 37.5 | No | 9010 | 160 | 12 | SCC | pT2bN2M0/IIIa |
| 21/M/65 | None | 30 | No | <40 | 253 | 3 | SCC | pT2aN0M0/Ib |
| 22/M/57 | Chest tightness | 36 | No | NA | 174 | 0 | ADC | cT2aN3M1b/IV |
| 23/F/57 | Chest tightness | 0 | TB | NA | 483 | 36 | ADC | cTxN2M1a/IV |
| 24/M/60 | Chest tightness | 0 | No | 4170 | 641 | 0 | ADC | cTxN1M1a/IV |
| 25/M/57 | Cough, bloody phlegm | 160 | No | 90 900 | 422 | 0 | SCC | pT1aN0M0/Ia |
| 26/M/46 | Chest pain | 0 | PCP | <40 | 412 | 32 | ADC | pT1aN0M0/Ia |
| 27/M/51 | None | 0 | No | 7630 | 435 | 0 | ADC | pT2aN1M0/IIa |
| 28/M/66 | Cough, fever | 0 | F | 21 300 | 113 | 0 | SCC | cT4N3M1a/IV |
| 29/M/76 | Cough, chest tightness | 0 | PCP, TB | NA | 325 | 24 | ADC | cTxN0M1b/IV |
| 30/M/58 | Cough, bloody phlegm | 52.5 | No | 10 400 | 210 | 0 | LCC | cT4N2M1a/IV |
| 31/M/63 | Cough, expectoration | 50 | TB | NA | NA | 24 | SCC | cT4NxM1b/IV |
| 32/M/62 | None | 80 | F | <40 | 401 | 168 | ADC | pT1aN0M0/Ia |
| 33/M/69 | None | 0 | No | NA | 574 | 36 | ADC | pT1aN0M0/Ia |
| 34/M/51 | None | 0 | No | NA | 147 | 60 | ADC | pT2aN1M0/IIa |
| 35/F/67 | Cough, fever | 0 | F | NA | 245 | 0 | ADC | cT2aNxM1a/IV |
| 36/M/55 | Chest pain, fever | 0 | F | 3860 | 207 | 0 | ADC | cT3N1M0/IIIa |
| 37/M/52 | Chest pain | 30 | TB | NA | 109 | 2 | ADC | cT3N3M1b/IV |
| 38/M/37 | Chest pain, cough, phlegm | 40 | No | <40 | 679 | 60 | SCLC | LD |
| 39/M/66 | Cough, phlegm | 0 | F, TB | NA | 8 | 20 | SCLC | ED |
| 40/F/68 | Cough, phlegm | 0 | No | NA | 173 | 96 | SCC | cT4N3M1a/IV |
AC, atypical carcinoid; ADC, adenocarcinoma; CC, chief complaint; c, clinical; ED, extensive disease; F, fungus; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; LCC, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; LD, limited disease; NA, not available; NTM, non‐tuberculosis mycobacteria; OPI, opportunistic pulmonary infection; p, pathological; PCP, Pneumocystis carinii pneumonia; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; TB, tuberculosis; TNM, tumor node metastasis.
Comparisons of associated factors between non‐advanced stages
| Factors | Stages |
| |
|---|---|---|---|
| I–IIIa | IIIb–IV | ||
| Smoking (+) | 7 | 8 | 0.49 |
| Smoking (−) | 12 | 7 | |
| OPI (+) | 6 | 10 |
|
| OPI (−) | 13 | 5 | |
| CD4+ T cell count | 313 | 255 | 0.31 |
| HAART (+) | 11 | 9 | 1.00 |
| HAART (−) | 7 | 6 | |
I–IIIa and advanced stages (IIIb–IV) of non‐small cell lung cancer with HIV infection.
HAART data unavailable in case 4 with stage Ib, thus patient data was excluded.
Bold indicates statistically significant difference.
(+), with; (−), without; CD4+, CD4 positive; HAART, highly active antiretroviral therapy; OPI, opportunistic pulmonary infection; CD4+ T cell count‐using Mann–Whitney test; smoking, OPI, HAART using Fisher's exact text.
Comparison of CT features of lung tumors between HIV patients with and without OPI
| CT features | OPI |
| |
|---|---|---|---|
| + | − | ||
| TD | 16 | 18 | 0.66 |
| TI | 4 | 2 | |
| Round/oval | 7 | 15 |
|
| Irregular | 9 | 3 | |
| Size (cm) | 5.34 ± 0.72 | 3.66 ± 0.41 |
|
| Adenopathy (+) | 16 | 14 | 0.72 |
| Adenopathy (−) | 4 | 6 | |
| PI (+) | 8 | 6 | 0.21 |
| PI (−) | 10 | 16 | |
| PT (+) | 14 | 8 | 0.34 |
| PT (−) | 8 | 10 | |
| Hydrothorax (+) | 9 | 4 | 0.20 |
| Hydrothorax (−) | 11 | 16 | |
Four patients with opportunistic pulmonary infection (OPI) had indeterminate lung cancers (e.g. tumors mixed with infection or atelectasis, tumors without concise origin), and two patients without OPI.
(+), with; (−), without; PI, pleural indentation; PT, pleural thickening; TD, tumor with determinate boarder; TI, tumor with indeterminate boarder.
Bold indicates statistically significant difference.
Figure 1A 44‐year‐old male treated with highly active antiretroviral therapy for 36 months complained of occasional bloody phlegm. (a) An irregular mass with a maximal diameter of 4.4 cm in the transverse section was located in the right lower lobe. He received antibiotic treatment, as the mass was interpreted as an infection and non‐tuberculosis mycobacteria was proven by sputum culture. (b) Eighteen months later, the mass had grown to 5.9 cm. Mucinous adenocarcinoma was histologically confirmed after radical resection (stage IIIa).
Figure 2A 46‐year‐old male treated with highly active antiretroviral therapy for 32 months complained of chest pain for two months. (b–d) A solid nodule with lobulation and pleural indentation in the left lower lobe was noticed in the lung window on chest computed tomography scan, which was more prominent and larger than it was two years before (a), when it was inconspicuous (white arrow) in the set of Pneumocystis carinii pneumonia. Adenocarcinoma was confirmed by wedge resection (stage Ia).